Patience is a virtue for big pharma buyers
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
SITC 2018 – The search for immuno-oncology combos continues
Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Esmo 2018 – Without overwhelming efficacy the me-too PD-1 chase is futile
Results from Tesaro, Sanofi, Novartis, Merck KGaA and others have come in thick and fast, but can any beat the entrenched leaders?
Esmo 2018 – Lynparza delivers a huge result in first-line ovarian cancer
A dramatic extension in progression-free survival in Astrazeneca's Solo-1 study raises the prospect of improving cure rates in ovarian cancer, though the impact…
Esmo 2018 – Encouraging early prostate data fail to lift Clovis
Response rates in BRCA-positive patients hint at Parp inhibitors’ potential in prostate cancer, but Clovis reins in hopes for a different genetic marker.
After Alnylam’s solo maiden launch, here comes the tricky bit
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
